Biodexa successfully appealed Nasdaq delisting by meeting minimum bid price requirement

From GlobeNewswire: 2024-10-15 16:15:00

Biodexa Pharmaceuticals PLC, a biopharmaceutical company listed on NASDAQ under BDRX, successfully appealed a Nasdaq delisting. The Nasdaq Hearings Panel granted an extension for the company to demonstrate compliance with the $1.00 minimum bid price requirement by evidencing a closing bid price of at least $1.00 per share for 20 consecutive trading days by October 31, 2024. Biodexa is developing innovative products for diseases with unmet medical needs, including eRapa for Familial Adenomatous Polyposis, tolimidone for type 1 diabetes, and MTX110 for aggressive rare brain cancer indications. Their headquarters and R&D facility are located in Cardiff, UK.



Read more at GlobeNewswire: Biodexa Announces Successful Appeal of Nasdaq Delisting